Search Results

PharmEnable Therapeutics, a UK drug discovery company, and Sosei Heptares (TSE: 4565), the international biopharmaceutical company

Sosei Group Corporation (“Sosei Heptares"; TSE: 4565) and Verily, an Alphabet precision health technology company, today announced the successful validation and nomination of a first G-protein-coupled receptor (GPCR) target into early drug discovery for immune-mediated diseases with an initial indication focus of inflammatory bowel disease (IBD).

Sosei Group Corporation, will hold an investor and press conference on ’s announcement; “Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC, Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company.”

Sosei Group Corporation and Cancer Research UK announce that the first patient has been dosed in a Phase I/IIa clinical trial evaluating Sosei Heptares’ orally available small molecule cancer immunotherapy drug HTL0039732 for advanced solid tumors.

Sosei Group Corporation will announce its earnings results and present operational highlights for the 12 months ended 31 December 2023 on Tuesday, 13 February 2024.

global techbio company PrecisionLife, pioneers in precision medicine for chronic diseases, will assess the precision medicine potential of a neuroscience target nominated by Sosei Heptares, an international biopharmaceutical group specialising in structure-based drug design targeting G protein-coupled receptors (GPCRs).

Sosei Group Corporation announces that Formosa Pharmaceuticals, Inc. has received approval from the US Food & Drug Administration for clobetasol propionate ophthalmic suspension 0.05%, for the treatment of post-operative inflammation and pain following ocular surgery.

Sosei Group Corporation provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Sosei Group Corporation and PharmEnable Therapeutics, a UK drug discovery company, announce they have expanded their collaboration to apply their respective technologies to drive novel drug discovery for a second neurological disease target.

Sosei Group Corporation, announces its President & CEO, Chris Cargill, will present at the 42nd Annual J.P. Morgan Healthcare Conference.